Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ: BCRX )

8.050 -0.090 (-1.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were trading higher Thursday after the company reported second-quarter financial results. The company reported revenue of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The company's market cap stands at $141.7 million.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021
Upgrades For SolarEdge Technologies Inc (NASDAQ: 
Via Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some... 
Via Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Thursday. The stock price moved up to $16.93 following the option alert. Sentiment: BULLISH... 
Via Benzinga
Unusual Options Activity Insight: BioCryst Pharmaceuticals
On Friday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up to $17.1. Sentiment: BULLISH Option... 
Via Benzinga
BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials for its oral Factor D inhibitor,... 
Via Benzinga
BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in... 
Via Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... 
Via Benzinga
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
There's more than one opportunity for it to do so. 
Via The Motley Fool
9 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $16.12. Sentiment... 
Via Benzinga
In Case Silver Gets Slammed More
The Fed is no longer your friend when it comes to silver. Time to consider limiting your downside risk here. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
BioCryst's Orladeyo Application Under Review In Israel For Hereditary Angioedema
The Israeli Ministry of Health has accepted for review BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) application for Orladeyo to prevent recurrent attacks in... 
Via Benzinga
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET on Thursday, 86 companies set new 52-week highs. Noteworthy Mentions: The largest company on a market cap basis to set a new 52-week high was Bank... 
Via Benzinga
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Forget AMC, GameStop: Analyst Names 2 New Reddit Stocks Traders Should Watch
Meme stocks AMC Entertainment Holdings Inc (NYSE: AMC) and GameStop Corp. (NYSE: GME) are on the move once again this week, fueled by targeted buying campaigns driven by Reddit... 
Via Benzinga
Is BioCryst a Good Stock to Buy Now?
This commercial-stage drugmaker trades for less than many of its clinical-stage peers. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
Why BioCryst Pharmaceuticals Stock Is Jumping Today
Investors appear to be increasingly optimistic about the outlook for its drug Orladeyo. 
Via The Motley Fool
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Is BioCryst Pharmaceuticals A Good Biotech Stock To Own?
Growing investor interest in the bio-pharmaceuticals industry, combined with various technology innovations leading to breakthrough drug trials, have allowed BCRX to generate $19.10 million in revenues... 
Via Talk Markets
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25... 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q1 2021 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.